Tonix Pharmaceuticals investor deck spotlights TONMYA fibromyalgia launch and late-stage pipeline plans
TNXP•Cash position and pipeline milestones
Tonix said it had about $185.5 million in cash and cash equivalents as of Mar. 31, 2026, with no debt, and expected runway into early Q2 2027.
Pipeline milestones include TNX-4800 Lyme prevention adaptive Phase 2 field study planned for 1H 2027 and TNX-1500 Phase 2 planned for 2H 2026.
TONMYA launch and early sales progress
Tonix highlighted commercialization progress for TONMYA, its FDA-approved fibromyalgia treatment, launched Nov. 17, 2025.
The company reported TONMYA net sales of $3.7 million in Q1 2026 and $5.1 million from Nov. 17, 2025 to Mar. 31, 2026.
Uptake tracked through May 1, 2026 showed more than 2,700 prescribers, about 5,618 patients and about 11,016 prescriptions.
